
Teoman Soysal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5944991/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naÃ⁻ve patients with chronic lymphocytic leukemia. Turkish Journal of Medical Sciences, 2021, 51, 348-354.	0.4	0
2	KRONİK LENFOSİTİK LĖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR (OTOİMMÜN OLAYLAR İLE İLİŞKİSİ. İstanbul Tıp Fakültesi Dergisi, 2021, 84, .	GEN PÜZ	ZEYLERİ VE
3	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia, 2021, 35, 3059-3072.	3.3	40
4	Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 549-557.	0.2	4
5	An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 3809-3820.	2.0	2
6	R-CHOP Chemotherapy Including Biosimilar Rituximab (Redditux ®) for De-Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single Center Experience. Blood, 2021, 138, 4585-4585.	0.6	1
7	The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience. Laboratory Medicine, 2020, 51, 259-264.	0.8	1
8	Trisomy-8-Positive Hematologic Malignancies Associated with Intestinal Behçet's Syndrome: Keep This Entity in Mind. Acta Haematologica, 2020, 143, 194-195.	0.7	1
9	Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Annals of Hematology, 2020, 99, 301-307.	0.8	4
10	Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology, 2020, 99, 2671-2677.	0.8	5
11	Copy-number variations in adult patients with chronic immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1277-1287.	1.0	3
12	Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythaemia Vera: a Multicentre Chart Review Study. Turkish Journal of Haematology, 2020, 37, 177-185.	0.2	1
13	Age-Related Co-Expression of BCOR and BCORL1 mRNA in Acute Myeloid Leukemia. Clinical Laboratory, 2020, 66, .	0.2	0
14	Deep sequencing of <i>BCR-ABL1</i> kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leukemia and Lymphoma, 2019, 60, 200-207.	0.6	11
15	The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J.) Tj ETQq1	1 0.78431 1.7	L4 _{_2} gBT /Ove
16	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e241.	0.2	3
17	The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e377-e384.	0.2	3
18	A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia. Turkish Journal of Haematology, 2019, 36, 230-237.	0.2	8

#	Article	IF	CITATIONS
19	The Real-Life Data on the Outcome of Hepatitis B Infection in Patients with B-Cell Lymphoproliferative Neoplasms Treated with Ibrutinib. Blood, 2019, 134, 4316-4316.	0.6	1
20	Comment and response to: the significance of early warning in chronic myeloid leukemia. Expert Review of Hematology, 2018, 11, 267-268.	1.0	0
21	Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology, 2018, 23, 212-220.	0.7	20
22	Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. Balkan Medical Journal, 2018, 35, 417-421.	0.3	4
23	Results of the Haematology Laboratory Survey: What has changed in 8 years?. Turkish Journal of Haematology, 2018, 35, 215-216.	0.2	2
24	Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 804-811.	0.2	20
25	Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors. Turkish Journal of Haematology, 2017, 34, 233-238.	0.2	3
26	Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience. Turkish Journal of Haematology, 2017, 34, 291-299.	0.2	7
27	The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients. Turkish Journal of Haematology, 2016, 33, 216-222.	0.2	14
28	Hematopoietic cell transplantation activity of Turkey in 2014: Ongoing increase in HCT rates. Transfusion and Apheresis Science, 2016, 54, 53-59.	0.5	4
29	Treatment of patients with immune thrombocytopenia admitted to the emergency room. International Journal of Hematology, 2016, 104, 216-222.	0.7	7
30	Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?. Expert Review of Hematology, 2016, 9, 919-921.	1.0	8
31	Personalized prophylaxis in people with hemophilia A: challenges and achievements. Expert Review of Hematology, 2016, 9, 1203-1208.	1.0	17
32	Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 272-277.	0.3	2
33	Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. Journal of Clinical Pathology, 2016, 69, 810-816.	1.0	5
34	Generic imatinib in the treatment of chronic myeloid leukemia: CerrahpaÅŸa experience. Journal of Oncology Pharmacy Practice, 2016, 22, 382-384.	0.5	3
35	Comparison of International Prognostic Index and NCCN-IPI in 324 patients with <i>de novo</i> diffuse large B-cell lymphoma: a multi-center retrospective analysis. Leukemia and Lymphoma, 2016, 57, 1211-1214.	0.6	6
36	Early Changes of Mannose-Binding Lectin, H-Ficolin, and Procalcitonin in Patients with Febrile Neutropenia: A Prospective Observational Study. Turkish Journal of Haematology, 2016, 33, 304-310.	0.2	5

#	Article	IF	CITATIONS
37	Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia. Blood, 2016, 128, 1905-1905.	0.6	0
38	Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode. Turkish Journal of Haematology, 2015, 32, 243-250.	0.2	9
39	Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?. Leukemia and Lymphoma, 2015, 56, 2995-2996.	0.6	4
40	Radotinib in the treatment of chronic phase chronic myeloid leukemia patients. Haematologica, 2015, 100, e39-e39.	1.7	7
41	Recurrent Monosomies Confirmed by Interphase FISH in Three Chronic Myeloid Leukemia Cases. Turkish Journal of Haematology, 2015, 32, 82-84.	0.2	0
42	Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide. Expert Review of Hematology, 2015, 8, 765-783.	1.0	3
43	The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment. Leukemia and Lymphoma, 2015, 56, 1554-1555.	0.6	2
44	The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?. Leukemia and Lymphoma, 2015, 56, 1182-1183.	0.6	3
45	Postoperative thrombotic thrombocytopenic purpura. Surgery Today, 2015, 45, 8-16.	0.7	14
46	Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias. Blood, 2015, 126, 4037-4037.	0.6	3
47	Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. Turkish Journal of Gastroenterology, 2015, 25, 233-233.	0.4	7
48	Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia. Blood, 2015, 126, 2783-2783.	0.6	1
49	Posttransplant Secondary Neoplasms: A Single Center Experience. Blood, 2015, 126, 5485-5485.	0.6	0
50	Haemophilic Arthropathy Is a Risk Factor for Reduced Bone Mineral Density and Vitamin D Deficiency. Blood, 2015, 126, 4685-4685.	0.6	0
51	New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition. Blood, 2015, 126, 77-77.	0.6	0
52	A reappraisal of the association between Behçet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clinical and Experimental Rheumatology, 2015, 33, S145-51.	0.4	20
53	The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study. Turkish Journal of Haematology, 2014, 31, 68-74.	0.2	27
54	Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish Journal of Haematology, 2014, 31, 374-380.	0.2	3

#	Article	IF	CITATIONS
55	Generics in chronic myeloid leukemia: current arguments for and against and the established evidence. Expert Review of Hematology, 2014, 7, 697-699.	1.0	18
56	Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leukemia Research, 2014, 38, 781-787.	0.4	33
57	Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature. Rheumatology, 2014, 53, 1136-1141.	0.9	37
58	The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 2935-2937.	0.6	14
59	Analysis of activation-induced cytidine deaminase mRNA levels in patients with chronic lymphocytic leukemia with different cytogenetic status. Leukemia and Lymphoma, 2014, 55, 326-330.	0.6	5
60	First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. British Journal of Haematology, 2014, 167, 139-141.	1.2	17
61	Two Cases of Autoimmune Hemolytic Anemia Secondary to Brucellosis: A Review of Hemolytic Disorders in Patients with Brucellosis. Internal Medicine, 2014, 53, 1153-1158.	0.3	16
62	The Prognostic Value of Serum APRIL Levels in Patients with Chronic Lymphocytic Leukemia. Blood, 2014, 124, 5648-5648.	0.6	0
63	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turkish Journal of Haematology, 2013, 30, 351-358.	0.2	14
64	Ecthyma Gangrenosum-like Lesions in a Febrile Neutropenic Patient with Simultaneous Pseudomonas Sepsis and Disseminated Fusariosis. Turkish Journal of Haematology, 2013, 30, 321-324.	0.2	7
65	B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node. Turkish Journal of Haematology, 2013, 30, 98-99.	0.2	1
66	Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study. ISRN Hematology, 2013, 2013, 1-9.	1.6	8
67	Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance. Blood, 2013, 122, 384-384.	0.6	1
68	The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2012, 29, 242-247.	0.2	0
69	JAK2V617FMutation Is Not Associated with Thrombosis in Behcet Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 421-426.	0.7	5
70	Hypereosinophilic Syndrome Associated with Simultaneous Intracardiac Thrombi, Cerebral Thromboembolism and Pulmonary Embolism. Internal Medicine, 2012, 51, 309-313.	0.3	7
71	Thrombotic Thrombocytopenic Purpura After Prophylactic Cefuroxime Axetil Administered in Relation to a Liposuction Procedure. Aesthetic Plastic Surgery, 2012, 36, 464-467.	0.5	7
72	Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm. Annals of Hematology, 2012, 91, 305-306.	0.8	4

#	Article	IF	CITATIONS
73	Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 442-445.	0.2	12
74	Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?. Leukemia Research, 2011, 35, e145-e146.	0.4	3
75	Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients. Turkish Journal of Haematology, 2011, 28, 186-192.	0.2	4
76	Pulmonary radiological findings in patients with acute myeloid leukemia and their relation to chemotherapy and prognosis: a single center retrospective study. Turkish Journal of Haematology, 2011, 29, 217-22.	0.2	6
77	Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence. Case Reports in Oncology, 2011, 4, 439-444.	0.3	3
78	Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica, 2011, 96, e15-e15.	1.7	25
79	ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method. Turkish Journal of Haematology, 2011, 28, 97-102.	0.2	4
80	Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia. Blood, 2011, 118, 1692-1692.	0.6	3
81	Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient. Journal of NeuroVirology, 2010, 16, 174-178.	1.0	9
82	17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leukemia and Lymphoma, 2007, 48, 311-320.	0.6	32
83	TheSOCS-1 gene methylation in chronic myeloid leukemia patients. American Journal of Hematology, 2007, 82, 729-730.	2.0	32
84	Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Annals of Hematology, 2005, 84, 609-613.	0.8	24
85	T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leukemia Research, 2004, 28, 229-236.	0.4	40
86	Primary Cutaneous Immunocytoma/Marginal Zone B-Cell Lymphoma: A Case with Unusual Course. American Journal of Dermatopathology, 2004, 26, 119-122.	0.3	9
87	Chronic Lymphocytic Leukemia in Turkey: Experience of a Single Center in Istanbul. Southern Medical Journal, 2004, 97, 240-245.	0.3	11
88	RELATIVE ERYTHROCYTOSIS OF PATIENTS WITH END STAGE RENAL FAILURE UNDERGOING CAPD. Renal Failure, 2002, 24, 29-35.	0.8	1
89	An overview of young CLL patients: a single-centre experience from Turkey. Haematologia, 2001, 31, 303-311.	0.2	7
90	The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey. Biology of Blood and Marrow Transplantation, 2000, 6, 370-374.	2.0	54

#	Article	IF	CITATIONS
91	Donor Leukocyte Infusions for Acute Myeloid Leukemia Relapsing after Stem Cell Transplantation. Acta Haematologica, 1998, 99, 49-51.	0.7	0